PetMed Express Inc. Common Stock (PETS)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a durable business bought at a sensible price. PetMed Express fails most of my tests. In fiscal 2026, ended 2026-03-31, revenue was $179.0 million and net income was -$57.3 million, or -$2.74 per diluted share. That follows fiscal 2025 revenue of $227.0 million and a net loss of $6.3 million, and fiscal 2024 revenue of $274.1 million and a net loss of $7.5 million. So sales are shrinking and the losses have worsened. In fiscal Q1 2027, the quarter ended 2026-06-30, revenue was $41.0 million and net income -$6.1 million, or -$0.28 per share. The company lost money again. Financial health is poor. Trailing free cash flow was -$27.8 million, a FairStock calculation, and FCF yield -100.9% against a $27.5 million market cap at the 2026-10-13 close. Debt is low, D/E 0.02, but that is cold comfort when operations consume cash. FairStock's 2/9 Piotroski and 0.55 Altman Z-Score point to weak fundamentals. ROE -78.56% and ROCE -20.05% show capital is being destroyed. Valuation? P/B 1.17 and P/E -0.93 are FairStock calculations. A negative P/E is meaningless; P/B only matters if assets earn returns. FairStock's 33/100 score and the Lynch category TURNAROUND, loss in latest year after earlier profits, suggest a broken business, not a classic bargain. A low price without earnings or cash flow is not value; it is speculation. I would need evidence of stabilized sales and positive cash generation before calling it cheap.

In plain English: PetMed Express sells pet medicines and health supplies, mostly for dogs, cats, and horses. The business looks weak: sales are falling, recent quarters and the last full year lost money, and it is using more cash than it brings in. The stock price is very low, but because the company is losing money, it does not look clearly cheap against its numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer